Induction and antagonism of antiviral responses in respiratory syncytial virus-infected pediatric airway epithelium

Journal of Virology

Volumn 89, Issue 24, 2015, Pages 12309-12318

  Villenave, Rémi ^a,f   Broadbent, Lindsay ^a   Douglas, Isobel ^b   Lyons, Jeremy D ^b   Coyle, Peter V ^c   Teng, Michael N ^d   Tripp, Ralph A ^e   Heaney, Liam G ^a   Shields, Michael D ^a,b   Power, Ultan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; INTERLEUKIN 29; JANUS KINASE; MYXOVIRUS RESISTANCE PROTEIN A; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 29; STAT PROTEIN; UNCLASSIFIED DRUG; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MX1 PROTEIN, HUMAN; MX2 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN;

ARTICLE; BRONCHUS MUCOSA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIUM CELL; HOSPITAL PATIENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN TISSUE; IMMUNOREGULATION; INFANT; INFECTION PREVENTION; INNATE IMMUNITY; LOWER RESPIRATORY TRACT; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS INDUCTION; VIRUS REPLICATION; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; RESPIRATORY MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VERO CELL LINE; VIROLOGY;

ANIMALS; CERCOPITHECUS AETHIOPS; HUMANS; INFANT; INTERLEUKINS; JANUS KINASES; MYXOVIRUS RESISTANCE PROTEINS; RESPIRATORY MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VERO CELLS;

EID: 84949895414     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02119-15     Document Type: Article

References (52)

1. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF. 2012. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A 109:5040-5045. http://dx.doi.org/10.1073/pnas.1110203109.
2. Guo-Parke H, Canning P, Douglas I, Villenave R, Heaney LG, Coyle PV, Lyons JD, Shields MD, Power UF. 2013. Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium. Am J Respir Crit Care Med 188:842-851. http://dx.doi.org/10.1164/rccm.201304-0750OC.
3. Glezen WP, Taber LH, Frank AL, Kasel JA. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543-546.
4. Chanock R, Roizman B, Myers R. 1957. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 66:281-290.
5. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69-77. http://dx.doi.org/10.1038/ni875.
6. Zorzitto J, Galligan CL, Ueng JJM, Fish EN. 2006. Characterization of the antiviral effects of interferon-alpha against a SARS-like coronavirus infection in vitro. Cell Res 16:220-229. http://dx.doi.org/10.1038/sj.cr.7310030.
7. Samuel CE. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14:778-809. http://dx.doi.org/10.1128/CMR.14.4.778-809.2001.
8. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80:4501-4509. http://dx.doi.org/10.1128/JVI.80.9.4501-4509.2006.
9. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flaño E, Schindler C, Grieves JL, Durbin RK, Kotenko SV, Durbin JE. 2010. Lambda interferon is the predominant interferon induced by influenzaAvirus infection in vivo. J Virol 84:11515-11522. http://dx.doi.org/10.1128/JVI.01703-09.
10. Jewell NA, Vaghefi N, Mertz SE, Akter P, Peebles RS, Bakaletz LO, Durbin RK, Flaño E, Durbin JE. 2007. Differential type I interferon induction by respiratory syncytial virus and influenza A virus in vivo. J Virol 81:9790-9800. http://dx.doi.org/10.1128/JVI.00530-07.
11. Hall CB, Douglas RG, Jr, Simons RL, Geiman JM. 1978. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr 93:28-32. http://dx.doi.org/10.1016/S0022-3476(78)80594-0.
12. Melendi GA, Coviello S, Bhat N, Zea-Hernandez J, Ferolla FM, Polack FP. 2010. Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus. Acta Paediatr 99:1517-1521. http://dx.doi.org/10.1111/j.1651-2227.2010.01862.x.
13. Scagnolari C, Midulla F, Pierangeli A, Moretti C, Bonci E, Berardi R, De Angelis D, Selvaggi C, Di Marco P, Girardi E, Antonelli G. 2009. Gene expression of nucleic acid-sensing pattern recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis. Clin Vaccine Immunol 16:816-823. http://dx.doi.org/10.1128/CVI.00445-08.
14. Witte K, Witte E, Sabat R, Wolk K. 2010. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 21:237-251. http://dx.doi.org/10.1016/j.cytogfr.2010.04.002.
15. Okabayashi T, Kojima T, Masaki T, Yokota S-I, Imaizumi T, Tsutsumi H, Himi T, Fujii N, Sawada N. 2011. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 160:360-366. http://dx.doi.org/10.1016/j.virusres.2011.07.011.
16. Donnelly RP, Kotenko SV. 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30:555-564. http://dx.doi.org/10.1089/jir.2010.0078.
17. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44:896-906. http://dx.doi.org/10.1002/hep.21312.
18. Haller O, Kochs G. 2011. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 31:79-87. http://dx.doi.org/10.1089/jir.2010.0076.
19. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA. 2007. Respiratory syncytial virus NS1 protein degrades STAT2 by using the elongin-cullin E3 ligase. J Virol 81:3428-3436. http://dx.doi.org/10.1128/JVI.02303-06.
20. Ling Z, Tran KC, Teng MN. 2009. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 83:3734-3742. http://dx.doi.org/10.1128/JVI.02434-08.
21. Spann KM, Tran K-C, Chi B, Rabin RL, Collins PL. 2004. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol 78:4363-4369. http://dx.doi.org/10.1128/JVI.78.8.4363-4369.2004.
22. Touzelet O, Loukili N, Pelet T, Fairley D, Curran J, Power UF. 2009. De novo generation of a non-segmented negative-strand RNA virus with a bicistronic gene. Virus Res 140:40-48. http://dx.doi.org/10.1016/j.virusres.2008.10.019.
23. Villenave R, O'Donoghue D, Thavagnanam S, Touzelet O, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF. 2011. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells. Virol J 8:43. http://dx.doi.org/10.1186/1743-422X-8-43.
24. Techaarpornkul S, Barretto N, Peeples ME. 2001. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 75:6825-6834. http://dx.doi.org/10.1128/JVI.75.15.6825-6834.2001.
25. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of theM2mRNAin gene expression and provides a capability for vaccine. Proc Natl Acad Sci U S A 92:11563-11567. http://dx.doi.org/10.1073/pnas.92.25.11563.
26. Webster Marketon JI, Corry J, Teng MN. 2014. The respiratory syncytial virus (RSV) nonstructural proteins mediate RSV suppression of glucocorticoid receptor transactivation. Virology 449:62-69. http://dx.doi.org/10.1016/j.virol.2013.11.014.
27. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen TN, Binz H. 1997. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virusGprotein fragment. Virology 230:155-166. http://dx.doi.org/10.1006/viro.1997.8465.
28. Villenave R, Touzelet O, Thavagnanam S, Sarlang S, Parker J, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF. 2010. Cytopathogenesis of Sendai virus in well-differentiated primary pediatric bronchial epithelial cells. J Virol 84:11718-11728. http://dx.doi.org/10.1128/JVI.00798-10.
29. Heaney LG, Stevenson EC, Turner G, Cadden IS, Taylor R, Shields MD, Ennis M. 1996. Investigating paediatric airways by non-bronchoscopic lavage: normal cellular data. Clin Exp Allergy 26:799-806. http://dx.doi.org/10.1046/j.1365-2222.1996.d01-385.x.
30. Coyle PV, Ong GM, O'Neill HJ, McCaughey C, Ornellas D De, Mitchell F, Mitchell SJ, Feeney SA, Wyatt DE, Forde M, Stockton J. 2004. A touchdown nucleic acid amplification protocol as an alternative to culture backup for immunofluorescence in the routine diagnosis of acute viral respiratory tract infections. BMC Microbiol 4:41. http://dx.doi.org/10.1186/1471-2180-4-41.
31. Bousse T, Chambers RL, Scroggs RA, Portner A, Takimoto T. 2006. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res 121:23-32. http://dx.doi.org/10.1016/j.virusres.2006.03.012.
32. Taylor CE, Webb MS, Milner AD, Milner PD, Morgan La, Scott R, Stokes GM, Swarbrick aS, Toms GL. 1989. Interferon alfa, infectious virus, and virus antigen secretion in respiratory syncytial virus infections of graded severity. Arch Dis Child 64:1656-1660. http://dx.doi.org/10.1136/adc.64.12.1656.
33. Lo MS, Brazas RM, Holtzman MJ. 2005. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79:9315-9319. http://dx.doi.org/10.1128/JVI.79.14.9315-9319.2005.
34. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. 2000. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273:210-218.http://dx.doi.org/10.1006/viro.2000.0393.
35. Stoltz M, Klingström J. 2010. Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. J Virol 84:9140-9148. http://dx.doi.org/10.1128/JVI.00717-10.
36. Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, Casanova J-L, Haller O, Kochs G. 2007. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 81:7776-7785. http://dx.doi.org/10.1128/JVI.00546-06.
37. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. 2006. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 344:328-339. http://dx.doi.org/10.1016/j.virol.2005.09.009.
38. Takeuchi O, Akira S. 2009. Innate immunity to virus infection. Immunol Rev 227:75-86. http://dx.doi.org/10.1111/j.1600-065X.2008.00737.x.
39. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat Immunol 7:131-137. http://dx.doi.org/10.1038/nrm1835.
40. Ren J, Liu T, Pang L, Li K, Garofalo RP, Casola A, Bao X. 2011. A novel mechanism for the inhibition of interferon regulatory factor-3-dependent gene expression by human respiratory syncytial virus NS1 protein. J Gen Virol 92:2153-2159. http://dx.doi.org/10.1099/vir.0.032987-0.
41. Spann KM, Tran KC, Collins PL. 2005. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-κB, and proinflammatory cytokines. J Virol 79:5353-5362.http://dx.doi.org/10.1128/JVI.79.9.5353-5362.2005.
42. Swedan S, Musiyenko A, Barik S. 2009. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 83:9682-9693. http://dx.doi.org/10.1128/JVI.00715-09.
43. Killip MJ, Young DF, Ross CS, Chen S, Goodbourn S, Randall RE. 2011. Failure to activate the IFN-γ promoter by a paramyxovirus lacking an interferon antagonist. Virology 415:39-46. http://dx.doi.org/10.1016/j.virol.2011.03.027.
44. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.AmJ Physiol Gastrointest Liver Physiol 289:G960-G968. http://dx.doi.org/10.1152/ajpgi.00126.2005.
45. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4:e1000017. http://dx.doi.org/10.1371/journal.ppat.1000017.
46. Donnelly RP, Dickensheets H, O'Brien TR. 2011. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 32: 443-450. http://dx.doi.org/10.1016/j.it.2011.07.002.
47. Larkin J, Jin L, Farmen M, Venable D, Huang Y, Tan S-L, Glass JI. 2003. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 23:247-257. http://dx.doi.org/10.1089/107999003321829962.
48. Sainz B, Halford WP. 2002. Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 76:11541-11550. http://dx.doi.org/10.1128/JVI.76.22.11541-11550.2002.
49. Scagnolari C, Trombetti S, Alberelli A, Cicetti S, Bellarosa D, Longo R, Spanò A, Riva E, Clementi M, Antonelli G. 2007. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. Intervirology 50:156-160. http://dx.doi.org/10.1159/000098242.
50. Huguenin A, Moutte L, Renois F, Leveque N, Talmud D, Abely M, Nguyen Y, Carrat F, Andreoletti L. 2012. Broad respiratory virus detection in infants hospitalized for bronchiolitis by use of a multiplex RT-PCR DNA microarray system. J Med Virol 84:979-985. http://dx.doi.org/10.1002/jmv.23272.
51. Richard N, Komurian-Pradel F, Javouhey E, Perret M, Rajoharison A, Bagnaud A, Billaud G, Vernet G, Lina B, Floret D, Paranhos-Baccalà G. 2008. The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis. Pediatr Infect Dis J 27:213-217. http://dx.doi.org/10.1097/INF.0b013e31815b4935.
52. Martin ET, Kuypers J, Wald A, Englund JA. 2012. Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children. Influenza Other Respir Viruses 6:71-77. http://dx.doi.org/10.1111/j.1750-2659.2011.00265.x.